Any intelligent investor can see the obvious value in MYL at these levels and will be taking a position with a very reasonable expectation of a nice return over the remainder of the year. Ditto for TEVA, same dynamics in place there as well.
True, but those rate hikes, even with 25 bp intervals tend to depress the overall market and MYL has a relatively High BETA. None the less I'm holding my position and expecting a profit with little interference over time. I just don't think MYL will suddenly spike higher in a very short time, not without some unforeseen event, like a buyout, which could happen.
I'm Long MYL, but let's get real here. I'm sure it will see $45 and beyond but not next week, not in this choppy market with the Fed announcing interest rate hikes ahead this year. Year end MYL should be at $50 plus, there's no miracle growth factor with MYL, just a distinct value play at an unreasonably low PPS. TEVA fits that same set as well.
It does hit the bottom line when acquisitions take place and a pharma co. has to conduct R&D to add to its pipeline. But the realistic view is to look ahead and see that these costs ultimately produce the growth that will drive PPS higher over time. MYL is growth and at these price levels value as well. Smart investors see that and take positions here.
These levels for such a growing profitable company are likely to find new suitors with new buyout prices, and this time the MYL board may have to take it instead of rejecting such an obvious boon to stock holders. May well happen this year.
Pharma companies posted much better results this quarter compared to the larger market which took a dive today. TEVA and MYL both up strongly today on high volume. Sector rotation into solid pharma like these two in place, both solid aggressive companies with demonstrated pipelines, traders, value and growth investors will push the PPS higher over the next month, $48 by June 12th is my conservative estimate.
In a quarter that generally showed less than desirable results, the pharma industry is posting good numbers. TEVA and MYL up large on a market pullback today and the trend most likely to continue as investors scramble for Growth and Value, which both issues display. $48 on Myl by June 12th is looking achievable.
Decent report Q1 and forecast intact, solid business global distribution, aggressively expanding through acquisitions and increasing product lines. That's a growth strategy, and on a day when the markets are trending down Myl is up on that strong volume. Should tell you that buying MYL here is a winning strategy. Add Teva to that for all the same reasons, both MYL and TEVA are growth and value wrapped up and waiting at this level.
Both Teva and Myl are solid profitable companies operating on a global scale and aggressively marketing new drugs and adding companies to their production bases that are synergistic and add to future earnings. Both are among the best values in the entire market at these absurdly low levels.
Both are distinctly more valuable than the market is pricing them at, solid companies with good growth ahead. In this market that's a hard combination to find. Buy them at this level and just don't worry about it, you'll be nicely surprised by year end.
I hope so, I'm not selling my MYL at this level, in fact I've added to my MYL position during this downturn. But I'm uncertain the turnaround will happen this quarter based on what analysts keep predicting as lower earnings.
Both solid companies with bright futures dragged down unrealistically on the heels of Perrigo problems and soft forecast for 2016. Typical market over reaction and a distinct opportunity to pick up shares of both MYL and TEVA.
Or you could have opened a position and be making money right now. Don't be confused by the over reaction to a single analysis that described a bleak picture for US going forward. UA is a solid company that commands a healthy multiple because it's still growing. Sure there are hiccups, volatility, but in the next 8 weeks you could be reaping in a large gain by adding on these pullbacks.
There is volatility in this market generally, UA is no exception, but they have a good business model and are successfully marketing a popular consumer item. Sure it doesn't move straight up in PPS, gives you a chance to average in or add to an existing position. In UA's case that's more of an opportunity than a detriment.
UA is a growing company with a popular line of apparel, they will eventually rein in the production costs and increase the bottom line and the customer base for their products continues to grow. That's a winning combo going forward.
gearhead, actually the negative report has some analysts describing it as being negative because so many wall street types are plugged into golf and tournament results.
I agree that Cramer is often off target and as such shouldn't be given too much credence. But I sure don't want socialists like Warren or Sanders meddling in public communications and limiting free speech on any level. This scapegoating of US corporations for all the US ills is just Marxist "class warfare" rhetoric rolled out again by the ultra leftists who've seized power in the US.
The masters golf failure of Speitth, or however his name is spelled, was the catalyst for the sudden devaluation of UA shares, and it was way overdone largely because Wall Street people watch golf tourneys. But Golf is hardly even part of the financial story for UA. Take advantage of the irrational devaluation in UA over an essentially "non-event" that won't impact results. Short term gains practically locked in for alert traders who seize this opportunity.
When ever I shop at a WFM it's always packed, parking overflowing with shoppers. Yeah, they've got competitors in the health food market place, but none of them have the numbers of shoppers constantly coming and going from opening to close at each store that WFM has. Hard to see it linger at these low levels with so much repeat business and busy stores.
Sector rotation likely into banks as momentary EU scare dies down. I'll take the modest gains that both C and BAC look to garner over the next month. More of a sure thing than most other issues at this juncture of increased volatility.